Related Industry Reports:
- Neuronal Nicotinic Receptors - June 2008
- Psychotherapeutics: Antidepressants, Antipsychotics, Antianxiety Drugs, World Market
- Neuronal Nicotinic Receptors - July 2008
- The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
- Neuronal Nicotinic Receptors - October 2008
A Multicenter, Open-Label Trial to Evaluate the Quality of Life in Adults With ADHD Treated With Long-Acting Methylphenidate (OROS MPH): Concerta Quality of Life (CONQoL) Study.
Journal of attention disorders 2012 Feb 14; In press
Mattos P, Louzã MR, Palmini AL, Oliveira IR, Rocha FL
Institute D'Or of Research and Learning Universidade Federal do Rio de Janeiro, Brazil; Institute D'Or of Research and Learning.
Literature provides few studies on the effectiveness of methylphenidate in ADHD, such as Quality of Life (QoL). Objective: To assess the effectiveness of Methyphenidate OROS formulation (OROS MPH) through QoL in adults with ADHD. Method: A 12-week, multicenter, open-label trial involving 60 patients was used. The measures used were Adult Self-Rating Scale, Adult ADHD Quality of Life Scale (AAQoL), State and Trait Anxiety Inventory (STAI), Hamilton Depression Rating Scale (HAM-D), Clinical Global Impression (CGI), and safety measures. A significance statistic level of 5% was adopted. Results: Analyses included 60 patients (66.7% male; M age = 31.1 years) for safety and 58 patients for effectiveness. All AAQoL subscales improved from baseline to Week 12 (p < .0001), as well as the Total AAQoL (p < .0001). A significant reduction on Clinical Global Impression-Improvement (CGI-I), HAM-D, STAI, and ASRS scores was observed (p < .0001). No serious adverse event was reported. Conclusion: Treatment of adult ADHD patients with OROS MPH improves QoL. (J. of Att. Dis. 2012; XX(X) 1-XX).